Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06993480 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 17, 2026 → Jul 27, 2027
See other at-risk trials from Ausper Biopharma Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 17, 2026 to Jul 27, 2027
    • Study completion pushed from Feb 9, 2027 to Nov 27, 2027
    • Secondary endpoints: 13 to 16
    • Study description shortened, about 69 words
    v5
  2. Enrollment reduced: 30 → 20 participantsv4 Show 5 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study completion pushed from Dec 1, 2026 to Feb 9, 2027
    • Primary completion date: Jun 30, 2026 to Jul 17, 2026
    • Start date: Jun 18, 2025 to Jul 15, 2025
    • Site details revised
  3. Eligibility criteria expanded, about 10 words
    • Study description shortened, about 1 word
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 19, 2025 to Jun 18, 2025
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues.
Trial Details
NCT Number NCT06993480
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions
(from sponsor)		 Chronic Hepatitis B
Related terms Hepatitis B, Chronic
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov